Methods and systems for reducing therapy variability and increasing therapeutic efficacy and persistence

By monitoring and adjusting energy delivery parameters in real time in the lung treatment system, the treatment inconsistency problem caused by changes in tissue electrical characteristics in unipolar RF ablation technology is solved, and a more efficient and lasting treatment effect of lung disease is achieved.

CN119055347APending Publication Date: 2024-12-03HOLAIRA INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202411188368.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-12-07
Filing Date
2017-12-07
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing unipolar RF ablation technology is difficult to effectively compensate and adjust due to changes in the electrical characteristics of patients' tissues when treating lung diseases.

Method used

Using a system including catheter assembly, ablation assembly, sensor and controller, to ensure continuous treatment process by measuring tissue impedance, temperature and current, dynamically adjusting energy delivery parameters such as power and current to achieve a constant therapeutic output and impedance drop percentage Sex and efficiency.

Benefits of technology

By monitoring and adjusting energy delivery parameters in real time, it can effectively compensate for the variability of patient tissue and electrode contact, improve the consistency and effectiveness of ablation treatment, reduce non-target tissue damage, and enhance the durability and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055347A_ABST
    Figure CN119055347A_ABST
Patent Text Reader

Abstract

Methods and systems for ablating target tissue, such as in or along an airway, include adjusting one of power and current of the system to achieve a therapeutic output or parameter. The therapeutic output may include current, power, delivered energy, impedance drop percentage, based impedance ratio, impedance slope percentage, and / or airway wall impedance. The power and / or current of the system may vary within a certain maximum threshold, such as a power, current, and / or impedance threshold, to achieve a desired output parameter target during part or all of the treatment times. The systems and methods reduce changes in therapeutic efficacy due to electrical characteristics of patient tissue and / or variability of electrode contact.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application is a divisional application of Chinese Patent Application No. 201780083761.X, and claims the benefit of U.S. Provisional Application No. 62 / 431,283 filed on December 7, 2016, which is hereby incorporated by reference in its entirety. Field of the Invention

[0003] The present invention relates generally to treatment systems and methods, and more particularly, to pulmonary treatment systems and methods for controlling energy delivery to the airways while compensating for changes in the electrical properties of the patient's tissue. Background of the Invention

[0005] Lung diseases are some of the most common medical conditions, affecting tens of millions of people in the United States alone. Lung diseases are caused by problems in the airways that interfere with normal breathing. Many of these diseases require medical care or intervention to restore proper lung function and improve the patient's overall quality of life. Some of the more common lung diseases include asthma and chronic obstructive pulmonary disease, or COPD. Symptoms of lung diseases such as COPD and asthma vary, but generally include a persistent cough, shortness of breath, wheezing, chest tightness, and rapid breathing. Often, these symptoms are exacerbated when engaging in some strenuous activity (e.g., running, jogging, brisk walking, etc.). However, if the disease is allowed to progress unchecked, these symptoms may be noticed when engaging in non-strenuous activities. Over time, especially if medical care is not sought, a person's daily activities will become severely impaired, reducing the overall quality of life.

[0006] Many lung diseases, both acute and chronic, often involve pathological conditions associated with airway inflammation. When this inflammation develops in the airways, the infiltrating inflammatory cells cause damage to the bronchial or lung tissue, which ultimately leads to respiratory dysfunction characteristic of lung disease, such as reduced respiratory flow rate or oxygen exchange capacity. Over time, this inflammation can lead to obstruction of the airway lumen, thickening of the airway walls, and changes in structures within or around the airway walls. Airway obstruction can significantly reduce the amount of gas exchanged by the lungs, leading to dyspnea. Obstruction of the airway lumen can be caused by excessive intraluminal mucus, edema fluid, or both. Thickening of the airway wall can be attributed to excessive contraction of airway smooth muscle, hypertrophy of airway smooth muscle, hypertrophy of mucous glands, inflammation, edema, or a combination of these. Changes in the structures surrounding the airways (such as destruction of the lung tissue itself) can lead to loss of circumferential traction of the airway wall and subsequent narrowing of the airway. In general, lung diseases such as COPD and asthma are the result of a complex interaction of local inflammatory cytokines, inhaled irritants (e.g., cold air, smoke, allergens, or other chemicals), systemic hormones (e.g., cortisol and adrenaline), local nervous system input (i.e., nerve cells contained entirely within the airway wall that can produce local reflex stimulation of smooth muscle cells and mucous glands), and central nervous system input (i.e., nervous system signals transmitted from the brain to smooth muscle cells and mucous glands via the vagus nerve).

[0007] Asthma can also include acute attacks or attacks of additional airway narrowing caused by contraction of hyperresponsive airway smooth muscle that significantly increases airflow resistance. Asthma symptoms include recurrent episodes of shortness of breath (e.g., shortness of breath or dyspnea), wheezing, chest tightness, and coughing. In addition, COPD (commonly referred to as emphysema) is characterized by changes in lung tissue surrounding or adjacent to the airways of the lungs. Emphysema may involve the destruction of lung tissue (e.g., alveolar sacs), which results in reduced gas exchange and reduced circumferential traction applied to the airway wall by the surrounding lung tissue. The destruction of alveolar tissue limits the inflow of oxygen-rich air and the proper function of healthier tissues, resulting in significant shortness of breath. Exposure to chemicals or other substances (e.g., tobacco smoke) may significantly accelerate the rate of tissue damage or destruction. In addition, chronic bronchitis is another type of COPD, characterized by contraction of airway smooth muscle, smooth muscle hypertrophy, excessive mucus production, hypertrophy of mucous glands, and inflammation of the airway walls. Like asthma, these abnormalities are the result of a complex interaction of local inflammatory cytokines, inhaled irritants, systemic hormones, local nervous systems, and the central nervous system. Unlike asthma, where airway obstruction may be largely reversible, airway obstruction in chronic bronchitis is primarily chronic and permanent.

[0008] Treatment of pulmonary disease includes reducing exposure to noxious substances, administering medications (e.g., bronchodilators, steroids, phosphodiesterase inhibitors, theophylline, antibiotics, etc.), performing pulmonary therapy (e.g., oxygen therapy, pulmonary rehabilitation), and surgical intervention (e.g., bronchial thermoplasty). Unfortunately, drug therapy requires patient compliance, often causes harmful side effects, and does not necessarily treat the underlying cause of the disease. Similarly, surgical intervention can lead to disruption of smooth muscle tone and nerve function, making it impossible for patients to respond favorably to inhaled irritants, systemic hormones, and local and central nervous system inputs.

[0009] An alternative approach to treating lung disease is known as targeted pulmonary denervation. The method utilizes ablation (such as monopolar or bipolar radiofrequency (RF) ablation) to selectively treat a target area within the airway wall (e.g., an anatomical structure in the matrix) through an ablation component while protecting surface tissues, such as the surface of the airway wall. For example, if necessary or desired, mucus glands can be damaged to reduce the production of sufficient amounts of mucus to prevent mucus accumulation that causes increased airflow resistance, while retaining sufficient mucus production to maintain effective mucociliary transport. It is also possible to damage nerve branches / fibers that pass through the airway wall or other anatomical features in the airway wall.

[0010] A specially designed catheter allows the introduction of an ablation assembly, which typically includes one or more foldable electrodes or energy transmitters, connected to an expandable member (e.g., a balloon), into the patient's airway through a delivery device. The delivery device can be a guide tube, a delivery sheath, a bronchoscope, or an endoscope, and can include one or more observation devices, such as an optical observation device (e.g., a camera), an optical system (e.g., a set of lenses), an optical fiber, a CCD chip, etc. Once positioned in the desired area of ​​the airway (e.g., the left and / or right mainstem bronchus), the expandable member expands to position the one or more electrodes in contact with the airway wall.

[0011] Energy (such as RF energy) is supplied to the energy transmitter to ablate the target tissue that causes the lesion to form, thereby temporarily or permanently damaging the target tissue, thereby affecting, for example, weakening the nerve signals transmitted to or from the part of the lung associated with the target tissue. At the same time, a coolant is provided through a catheter, which is guided to one or more electrodes and enters an expandable member or balloon. This allows cooling of surface tissue in contact with the electrodes as well as adjacent tissue. The size, shape and depth of the lesion are determined by the flow rate and temperature of the coolant and the energy supplied to the energy transmitter. For example, devices, systems and methods for such procedures can be found in one or more of U.S. Patent No. 8,088,127 entitled "Systems, Components and Methods for Treating Bronchial Trees" and U.S. Patent Application Publication No. 2011 / 0152855 entitled "Delivery Device with Coolable Energy Transmitting Components" (both of which are incorporated herein by reference in their entirety).

[0012] In order to ensure that most or all of the target nerves extending along the airway are treated, it is generally desirable to form peripheral lesions at all or most of the circumference of the airway wall. Due to design limitations or preferences, the electrodes or energy transmitters may not extend around the entire circumference of the airway wall. Therefore, peripheral lesions can be formed by ablating tissue while slowly rotating the ablation assembly or by positioning the ablation assembly in a series of rotational positions (at each rotational position, energy is delivered for a desired period of time). Adjacent lesions then become continuous and form a circumferential band around the airway wall. Additionally or alternatively, the catheter can be repositioned axially to treat other locations distal or proximal to the first treatment site in the airway.

[0013] Regarding the monopolar RF ablation system, the system generally includes two separate monopolar electrodes: an active electrode (i.e., the energy transmitter of the ablation component) and a discrete electrode (e.g., a pad), which combines with the patient's body to form an electrical circuit. The active electrode is designed to focus the current or power on the treatment target to produce the desired tissue effect, such as ablation. The discrete electrode is positioned at a location of the patient away from the surgical site and has a relatively large surface area, which is designed to spread or disperse the current to prevent or reduce the occurrence of non-target tissue damage. However, the variability of the electrical properties of the patient's tissue inserted between the two electrodes of the monopolar system affects the consistency of the treatment effect.

[0014] The variability of the expected effect under constant ablation parameters (i.e., constant power, current, and / or time) is well-known in the field of monopolar RF ablation. A variety of methods can be found in the literature to counteract this inherent variability. These methods include monitoring the electrode / tissue interface temperature, tissue temperature, impedance changes during energy delivery, and the force applied to the electrode / tissue interface to maintain contact.

[0015] There remains a need for improved systems, methods, and algorithms for tissue treatment to better address the challenges of variability in monopolar RF ablation and to compensate for variability in treatment, including variability in patient tissue and / or electrode / tissue contact. SUMMARY OF THE INVENTION

[0017] Embodiments of the present invention relate to a pulmonary treatment system comprising a catheter assembly including a targeted pulmonary denervation (TLD) device, such as an RF, microwave or ultrasound catheter, and generally comprising an elongated shaft having a proximal portion and a distal portion and an ablation assembly connected to the distal portion of the shaft, the ablation assembly comprising an expandable member (such as a balloon or basket) and one or more electrodes or energy transmitters connected to the expandable member.

[0018] The catheter assembly is also connected to the system console by the handle assembly fluid and electrically connected, including coolant supply and return pool and energy supply (such as RF generator). The system also includes one or more sensors and controllers, for measuring treatment characteristics or output, such as, for example, tissue and energy characteristics, including but not limited to tissue impedance, tissue temperature, output current and / or voltage, etc., and for adjusting treatment parameters based on one or more treatment outputs. The controller can generally include a microprocessor that is operably connected to a volatile memory (such as RAM) and / or a non-volatile memory (such as flash memory medium, disk medium, etc.), for continuously or discretely collecting and storing output data from a sensor. As described below, the microprocessor is also operably connected to an energy transmitter and a generator, and is programmed to process and calculate the output data from the sensor and / or control the output of a generator and / or an energy transmitter according to an open-loop and / or closed-loop control loop scheme.

[0019] Methods and systems of embodiments of the present invention include varying one of the power and current of the system to achieve a treatment output or parameter. In a first embodiment, the generator power is varied within a maximum power threshold to achieve a constant current during the treatment time. In another embodiment, tissue impedance is measured during treatment and the impedance drop percentage is calculated. The current is varied within the maximum power threshold to achieve a desired impedance drop percentage during the treatment time.

[0020] In yet another embodiment, the generator power is varied within a maximum power threshold to achieve a constant current at a desired target current within the treatment time. Also throughout the treatment time, the impedance drop percentage is calculated. If a predetermined impedance drop percentage is reached before the desired target current is reached, the current is constant at that time for the remainder of the treatment time. If a predetermined impedance drop percentage is not reached within the treatment time, the current is maintained at the desired target current for the remainder of the treatment time.

[0021] In another embodiment of the invention, during the first treatment period, the power is varied to achieve the desired target current. At the end of the first treatment period, the power is held constant for the remainder of the treatment period. However, if the impedance during the second treatment period meets or exceeds the lower impedance value sampled during the first treatment period plus the predetermined impedance value, the system issues a warning or stops energy delivery altogether.

[0022] In another embodiment, during the first treatment time, the power or current is held constant at a desired value. At the end of the first treatment time, the power or current is changed within the maximum power limit to maintain a small positive percentage impedance slope, such as 1%-30%. The impedance slope is calculated by impedance measurement during the treatment. In this embodiment, if the impedance limit threshold is met or exceeded during the first treatment time, the system issues a warning or completely stops energy delivery. For the second treatment time, if the impedance limit threshold or the percentage impedance slope limit threshold is exceeded, the system issues a warning or completely stops energy delivery.

[0023] In another embodiment, the impedance of the airway wall is determined or approximately estimated throughout the treatment process to allow continuous adjustment of the current to maintain constant power deposited in the airway wall. The airway wall impedance can be determined or estimated using a split main electrode that serves as both a bipolar impedance sensing element and a monopolar effective electrode for focusing the treatment current. The airway wall impedance can be estimated by using another electrode that is placed in anatomically close proximity to the effective electrode in the airway (e.g., esophagus or adjacent blood vessels). By measuring the impedance between the two electrodes, an approximate value of the airway wall component of the total resistance can be determined.

[0024] The above summary is not intended to describe each example embodiment or every implementation of the present subject matter.The following figures and detailed description more particularly exemplify various embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The present subject matter may be more fully understood upon consideration of the following detailed description of various embodiments in conjunction with the accompanying drawings, in which:

[0027] Figure 1 is a treatment system according to an embodiment of the present invention;

[0028] Figure 2 is an ablation assembly according to an embodiment of the present invention;

[0029] Figure 3 According to the embodiment of the present invention Figure 1 Cooling circuits of treatment systems;

[0030] Figure 4 is a depiction of a monopolar RF ablation circuit according to an embodiment of the present invention;

[0031] Figure 5 yes Figure 4 A graph showing the total resistance of a circuit and the negative correlation between the current and time;

[0032] Figures 6A-6C is a test set of monopolar RF ablation circuits according to an embodiment of the present invention;

[0033] Fig. 7A and7B It is a depiction Figures 6A-6C A graph showing the general relationship between the average current and the % impedance drop during treatment for the test group;

[0034] Figure 8 is a model of a thermistor connected in series with a resistor to simulate an airway according to an embodiment of the present invention;

[0035] Fig. 9 is an impedance trace during ablation therapy according to an embodiment of the present invention;

[0036] Figures 10A-10C It is the linear regression curve of impedance ratio and impedance drop percentage, impedance ratio change and current;

[0037] Figures 11A-11C is a graph of maximum damage depth as a function of impedance drop percentage, impedance ratio change, and current;

[0038] Fig.12 is a process flow chart of a treatment method according to an embodiment of the present invention;

[0039] Fig.13 is a process flow chart of a treatment method according to another embodiment of the present invention;

[0040] Fig.14 is a process flow chart of a treatment method according to another embodiment of the present invention; and

[0041] Fig.15 is a process flow chart of a treatment method according to yet another embodiment of the present invention.

[0042] Although various modifications and alternative forms are possible for each embodiment, the details thereof have been illustrated by way of example in the drawings and described in detail. However, it should be understood that the claimed invention is not intended to be limited to the specific embodiments described. On the contrary, it is intended to cover all modifications, equivalents, and substitutes that fall within the spirit and scope of the subject matter defined by the claims.

[0043] Detailed Description of the Drawings

[0044] Throughout this disclosure, the words destruction, ablation, modulation, denervation will be used. It should be understood that these all refer to any neural manipulation that changes the action of the nerve. This can be a complete cessation of the signal (such as ablation or cutting), or it can be modulation, such as accomplished by partial or temporary interruption, pacing, etc.

[0045] Similarly, trachea is often used to describe the section in which the devices and methods are used. It should be understood that this is shorthand and is meant to include the trachea itself, and, where necessary, the left and right main bronchi and other parts of the pulmonary tree.

[0046] It should be noted that the pulmonary nerves mentioned in the present disclosure include not only the nerves that control the pulmonary system, but also any neural structures that can affect the behavior of the lungs. For example, components of the cardiac plexus or nerves that control the esophagus also interact with the airway and may cause asthma. The nerves may include nerve trunks along the outer wall of hollow blood vessels, nerve fibers in the walls of hollow blood vessels (such as tracheal walls and / or esophageal walls), nerves in the bridge between the trachea and the esophagus, or nerves in other positions. The left and right vagus nerves originate from the brainstem, pass through the neck and go down through the chest on either side of the trachea. These or a portion of these nerves can be targeted. The vagus nerve spreads into the nerve trunk, which includes the anterior and posterior pulmonary plexuses that surround the trachea, the left main bronchus, and the right main bronchus. The nerve trunk also extends along the branching airways of the bronchial tree. The nerve trunk is the main trunk of the nerve, including a bundle of nerve fibers that are bound together by a tough sheath of connective tissue. The vagus nerves, including their nerve trunks, along the trachea or other neural tissue along, near or located in the bronchial tree can be targeted, while branches running along, near or located in the esophagus can be untargeted and / or protected through the embodiments set forth below. Therapeutic devices in the form of tracheal devices can be positioned at different locations within the airway (e.g., the trachea, one of the main stem bronchi, or other structures of the bronchial tree).

[0047] The pulmonary branch of the vagus nerve along the left and right main bronchial centers is a particularly preferred target. The nerve trunk of the pulmonary branch extends along the distal airways of the left and right main bronchial and bronchial trees. The nerve trunk of the main trunk nerve includes a bundle of nerve fibers that are combined together by the tough sheath of connective tissue. Any number of operations can be performed to one or more nerve trunks to affect the lung parts associated with those nerve trunks. Because some nerve tissues in the nerve trunk network merge into other nerves (e.g., nerves connected to the esophagus, nerves through the chest and into the abdomen, etc.), specific parts can be targeted to minimize, limit or substantially eliminate the unnecessary damage of those other nerves.

[0048] Some of the fibers of the anterior and posterior pulmonary plexuses merge into small nerve trunks that run along the outer surface of the trachea and into the branching bronchi and bronchioles as they travel outward into the lungs. Along the branching bronchi, these small nerve trunks continue to branch off from each other and send fibers into the airway wall. Any nerve trunk or nerve tissue in the wall can be targeted.

[0049] In some embodiments, the aspects, embodiments, features, systems, devices, materials, methods and techniques described herein may be similar to the embodiments, features, systems, devices, materials, methods and techniques described in any one or more of the following applications and patents: PCT Publication Nos. WO2014 / 143898 and WO2015 / 038886 to Mayse et al.; U.S. Patent Application Publication Nos. 2011 / 0152855 to Mayse et al., 2011 / 0301587 to Deem et al., 2012 / 0310233 to Dimmer et al., 2013 / 0310822 to Mayse et al., 2014 / 0186341 to Mays, and 2014 / 0257271 to Mayse et al.; U.S. Patent Nos. 8,088,127 to Mayse et al., 8,172,827 to Deem et al., 8,483,831 to Hlavka et al., and 8,911,439 to Mayse et al. In addition, the systems and methods disclosed herein may employ any cooling system described in U.S. Patent Application Publication No. 2014 / 0276792 and PCT Publication No. WO2014 / 160422 to Kaveckis et al., and / or any processing system described in PCT Publication No. WO2015 / 089377 to Harshman et al. The disclosures of each of the above applications and patents are hereby incorporated by reference in their entirety, except for the claims and any obviously contradictory definitions.

[0050] According to certain embodiments of the present invention, the device can be configured to deliver radiofrequency energy to modulate or disable the pulmonary plexus. Although the illustrated embodiment is configured to deliver RF energy, many configurations may also be suitable for modulating catheter-based microwave antennas, high-energy pulsed electroporation, or similar energy forms.

[0051] RF energy can be delivered in traditional conductive mode RF, where energy is applied directly to the tissue through direct contact electrodes, or it can be delivered to the tissue by using capacitive coupling. In capacitive coupling, a slightly higher frequency signal is typically used compared to traditional RF, and the energy is delivered to the tissue through a dielectric, which is typically a cooling element. In one example of capacitive coupling, energy can be delivered across a cooling plate that prevents the contacted tissue surface from being damaged as the energy is delivered deeper into the target tissue.

[0052] RF energy can be delivered to different target areas, which may include but are not limited to neural tissue (e.g., vagus nerve tissue, nerve trunks, etc.), fibrous tissue, diseased or abnormal tissue (e.g., cancer tissue, inflamed tissue, etc.), cardiac tissue, muscle tissue, blood, blood vessels, anatomical structures (e.g., membranes, glands, cilia, etc.) or other target sites.

[0053] In RF ablation, when RF current passes through tissue, heat is generated due to tissue resistance. Tissue resistance causes power consumption equal to the square of the current multiplied by the tissue resistance. In order to ablate deep tissue, if a cooling device (such as a cooling plate or cooling balloon) is not used for active cooling, the tissue between the RF electrode and the deep tissue will become overheated. The cooling device can be used to keep the tissue near the electrode below the temperature that causes cell death or damage, thereby protecting the tissue. For example, cooling can prevent or limit overheating at the electrode-tissue interface. Overheating (for example, tissue temperature above 95°C to about 110°C) can cause coagulant formation, tissue drying, tissue carbonization, and explosive release of steam. These effects can lead to increased tissue resistance and reduced RF energy delivered to the tissue, thereby limiting the effective RF ablation damage depth. Active cooling can be used to produce significantly deeper tissue damage. The temperature of the coolant used for active cooling can be about 0°C to about 24°C. In some embodiments, the coolant and electrode produce damage at a treatment depth of at least about 3mm, while protecting the tissue at a shallower depth from fatal damage. In some embodiments, the lesions can be formed at a depth of about 3 mm to about 5 mm to injure the nerve tissue. Other temperatures and depths can be achieved.

[0054] like Figure 1 As shown, according to an exemplary embodiment, the RF therapy system 100 may include an ablation catheter assembly 101 having an elongated shaft 102 and an ablation assembly 106 connected to a first or distal end of the shaft 102, a positioning handle assembly 104 connected to a second or proximal end of the shaft 102, an optional insertion tube 107 movably connected to the shaft 102 between the ablation assembly 106 and the handle assembly 104, and a scope connection assembly 103 for connecting the catheter assembly 101 and the handle assembly 104 to a working channel of a delivery device (such as a flexible endoscope or bronchoscope).

[0055] refer to Figure 2 , the ablation assembly 106 may include one or more energy emitters 510 (such as electrodes or transducers) and an expandable member 520 (such as a balloon or basket). For example, the one or more energy emitters are configured to deliver energy in a form such as RF, microwave, or ultrasound. In an embodiment, the one or more energy emitters are connected to a catheter 540, which is configured to flow a coolant therethrough to cool the energy emitters 510. The catheter 540 is in fluid communication with the shaft 102 and the expandable member 520 to circulate the coolant. The ablation assembly 106 may include a coolant fluid path or cooling circuit to cool the surface of the energy emitters 510 and the expandable member 520, thereby protecting the surface tissue in contact with the energy emitters 510 and the surface tissue adjacent to the energy emitters 510 to achieve deep tissue ablation.

[0056] The ablation assembly 106 may optionally include a throttle valve 530 for regulating flow between the catheter 540 and the expandable member 520. The ablation assembly 106 may also optionally include a support wire 1214 (e.g., a nickel titanium wire) to provide additional axial, torsional, and flexion support for the expandable member 520 and the catheter shaft 102. Additional details of the ablation assembly 106 are described in U.S. Patent No. 8,088,127, entitled “Systems, Assemblies, and Methods for Treating the Bronchial Tree,” and U.S. Patent Application Publication No. 2011 / 0152855, entitled “Delivery Device with Coolable Energy Emitting Assembly,” both of which are incorporated by reference in their entirety.

[0057] In some embodiments, and with reference to Figure 1 , handle assembly 104 is connected to the proximal portion of the shaft 102 of the catheter assembly 101. Umbilical cable 120 is connected to one end of handle assembly 104 through a spill port 121 to connect the catheter assembly 101 flow and / or electrically connect to ancillary devices or accessories, such as power supply, energy (e.g., RF generator), fluid or coolant supply, heat exchanger and controller, preferably combined in the system console. Umbilical cable 120 may include, for example, a connection for an inlet and return fluid tube or lumen to connect the shaft 102 flow to a fluid or coolant supply from a console, the console optionally including a heat exchanger for cooling and / or heating the input fluid and one or more cables / connectors to electrically connect the shaft and / or ablation assembly to a power source, a thermocouple for temperature monitoring and / or a pressure sensor for coolant circuit pressure. Suitable handle assemblies are described in more detail in International Publication No. WO2015 / 089377A1 entitled "Catheter and Handle Assembly, System and Method", which is incorporated herein by reference in its entirety.

[0058] The catheter assembly 101 is further fluidically and electrically connected to a system console (not shown) via a handle assembly 104, which includes a coolant circuit containing a coolant supply and return reservoir (described below). Figure 3 600) and an energy supply such as an RF generator. The handle assembly 104 is configured to manipulate the distal portion or end of the shaft 102 during the administration of a therapy (such as targeted lung denervation (TLD) therapy) to axially and circumferentially manipulate the ablation assembly 106, the details of which are discussed in U.S. Patent No. 8,088,127 and U.S. Patent Application Publication No. 2011 / 0152855, both of which are incorporated by reference in their entirety.

[0059] like Figure 3As shown, the cooling circuit 600 includes a coolant supplied from a tank 601 of the system console through: an optional heat exchanger 603 of the system console, the handle 104, an inflow lumen in the shaft 102, a catheter 540 connected to the electrode 510, an expandable member 520, an outflow lumen in the shaft 102, the handle 104, and back to the system console. Non-limiting examples of system consoles can be found in U.S. Patent Application Publication No. 2013 / 0289556 entitled "Delivery Device with Coolable Energy Emitting Assembly" and U.S. Patent No. 8,489,192 entitled "Systems and Methods for Bronchial Dilation", which are incorporated by reference in their entirety. For example, the fluid circulation is completed by a peristaltic pump 605. In an alternative embodiment, the flow is reversed so that the coolant flows through the expandable member before flowing through the electrode.

[0060] Now return to reference Figure 2 As described above, the ablation assembly 106 includes an energy delivery element in the form of one or more RF electrodes 510. The electrodes 510 may be in contact with or close to the inner surface of the trachea. The RF electrodes 510 may output RF energy converted from DC or AC power provided by a generator, which passes through the tissue and is converted into heat. Heat results in formation losses. Using a coolant, the RF energy may be directed radially outward to the target tissue without causing significant damage to non-target tissue (e.g., tissue associated with the esophagus, tissue inside the trachea, tissue in front of the trachea, etc.). Various different surgeries, such as, for example, a portion of the trachea, the entire circumference of the trachea, a nerve resection of a target nerve trunk that travels to one or both lungs, etc. The nerve tissue is damaged to relax the muscle tissue in the bronchial tree, thereby expanding the airway to reduce airflow resistance in one or both lungs, thereby allowing more air to reach the alveolar sacs for the gas exchange process. A reduction in airway resistance may indicate that the passage of the airway is opening, for example, in response to a decrease in the nervous system input to these airways.

[0061] In an embodiment, ablation assembly 106 also includes sensors for monitoring temperature, inflation pressure, coolant flow rate, tissue impedance, current, power or other target parameters. Feedback from the sensors can be used to adjust the power and / or current delivered to the electrodes. The output energy can be adjusted to account for local changes in tissue that change local impedance, thereby avoiding excessive heating that may cause undesirable hot spots. Lesions can also be formed independently of regional tissue features.

[0062] In one embodiment, the ablation assembly has one or more sensors (not shown) located thereon and communicatively connected to a controller in the console. The controller can control the catheter assembly 101 based on signals from the sensors (e.g., pressure sensors, temperature sensors, thermocouples, current sensors, power sensors, impedance sensors, contact sensors, etc.). Sensors can also be placed along the elongated shaft 102 or at any other location.

[0063] The controller is configured to measure treatment characteristics or outputs (such as, for example, tissue and energy characteristics, including but not limited to tissue impedance, tissue temperature, output current and / or voltage, etc.), calculate certain mathematical outputs or relationships based on sensor readings, and / or for adjusting treatment parameters based on one or more treatment outputs. The controller may generally include a microprocessor operably connected to a volatile memory (e.g., RAM) and / or a non-volatile memory (e.g., flash memory media, disk media, etc.) for continuously or discretely collecting and storing output data from the sensors. As described below, the microprocessor is also operably connected to the energy emitter and the generator, and is programmed to process and calculate output data from the sensors, and / or control the output of the generator and / or energy emitter according to an open-loop and / or closed-loop control loop scheme.

[0064] The controller can be a closed-loop system or an open-loop system. For example, in a closed-loop system, electrical energy is delivered to the electrode 510 based on a feedback signal from one or more sensors, and the sensor is configured to transmit (or send) one or more signals indicating one or more tissue characteristics, energy distribution, tissue temperature, or any other measurable target parameter. Based on these readings, the controller adjusts the operation of the electrode 510. Optionally, in an open-loop system, the operation of the electrode 510 is set by user input. For example, the user can observe the tissue temperature or impedance readings and manually adjust the power and / or current level delivered to the electrode 510. Optionally, the power can be set to a fixed power mode. In other embodiments, the user can repeatedly switch between a closed-loop system and an open-loop system.

[0065] The Mathematics Behind Target Tissue Heating

[0066] Reference now Figure 4, and as described above, the monopolar RF ablation system 400 generally includes two separate electrodes: an active electrode 402 and a discrete electrode 404, and a system console 406 for powering the active electrode 402. The electrodes 402, 404 include an active electrode 402 (i.e., an energy transmitter of the ablation assembly as described above) and a discrete electrode 404 (e.g., a pad), which is combined with the patient's body (such as the airway A, chest TX, abdomen Abd, and legs Leg) to form a loop. All possible parts of the patient's body that do not include the airway will be referred to as body B. The active electrode 402 is designed to focus current or power on the treatment target, thereby producing the desired tissue effect, such as ablation. The discrete electrode 404 is placed on the patient's body away from the surgical site and has a relatively large surface area. This design is used to defocus or disperse the current, thereby preventing or reducing the occurrence of non-target tissue damage.

[0067] As mentioned above, in RF ablation, when RF current flows through tissue, heat is generated due to tissue resistance. Tissue resistance causes power consumption equal to the square of the current multiplied by the tissue resistance:

[0068] P=i 2 R T

[0069] where i is the current, and R T is the total resistance of the circuit, or the resistance in series, i.e. the airway walls, chest, abdomen, and legs of the body. As the mathematical relationship shows, the current is inversely proportional to the total resistance, e.g. Figure 5 Specifically, at constant power, as the current increases, the total resistance decreases, and based on the current and airway resistance R A Heat is generated in the target tissue of the airway wall.

[0070] According to the first law of thermodynamics, the change in energy in the airway system, ΔE A It can be expressed as the change in airway temperature ΔT A , mass m and specific heat c, such as:

[0071] ΔE A =mcΔT A ,

[0072] It can be rewritten to determine the volume V and density ρ, as

[0073] ΔE A =ρVcΔT A .

[0074] Realize that at steady state the energy in the airway is the power P input into the airway A Multiply by time t, the power is input into the airway, then

[0075] ΔE A =tPA ,

[0076] Then solve for ΔT A get:

[0077] ΔT A =P A t / ρVc

[0078] P A =(R A / (R A +R B ))×P T ,

[0079] ΔT A =(P T t / ρVc)×(R A / (R A +R B )).

[0080] Knowing this relationship, a test was performed to demonstrate that the increase in power can compensate for the bulk resistance R B The test also showed that the progress of activation could be monitored based on impedance changes and that the impedance drop could be altered by manual power changes. Figures 6A-6C As shown, the test consists of three groups of tests and includes: a small body resistance group (R A / R T =0.6), the large body resistance group (R A / R T =0.4), and a large body resistance group (R A / R T =0.4), which includes constant power (20W) for 30 seconds and a power increase (+10W) at 30 seconds for the remaining treatment time. Using the above formula, the power delivered to the airway at the initial power of each group is calculated as follows:

[0081] P 气道R.6 =20W*0.6=12W

[0082] P 气道R.4 =20W*0.4=8W.

[0083] Fig. 7A and 7BThe power delivery drive parameters are shown to match the small body resistance group. Specifically, there is a comparable impedance drop % after power delivery because the power delivery increases the tissue temperature which drives the impedance drop. There is also a comparable current after delivery because the near field resistance is similar to the small body resistance group, which drives similar ablation depth and tissue temperature.

[0084] Target tissue temperature changes as a function of impedance

[0085] like Figure 8 As shown, the airway to be treated can be modeled as a thermistor, which is a linear device whose resistance varies with temperature, generally showing a smaller resistance as temperature increases. The body (series resistors, such as the chest, abdomen, and legs) can be modeled as a fixed resistor, which is an electrical device whose resistance does not vary as a function of temperature. This model is based on the assumption that the literature shows that tissue conductance varies as a function of temperature. Therefore, the total resistance of the system includes R A (airway resistance represented by the thermistor) and R B (Total resistance of body / body).

[0086] Using this model, the airway resistance R A It can be expressed as a thermistor, and its governing equation is:

[0087]

[0088] where k is a constant representing the linear relationship between thermistor conductance and T A is the temperature of the airway thermistor. Rewriting the equation to solve for the airway temperature is as follows:

[0089]

[0090] Therefore, to find a measurable correlation for the change in airway temperature as a function of resistance:

[0091]

[0092] Since it is not possible to directly measure R A1 and R A0 , the following can be determined:

[0093] R T =R A +R B ,

[0094] and

[0095] R A1 =R T1 -R B1

[0096] R A0=R T0 -R B0 .

[0097] Therefore, according to the above equation,

[0098]

[0099] Then, multiply everything on the right side of the equation by 1 to get:

[0100]

[0101] Now, recall for modeling purposes that the drag on the body does not change because:

[0102] R B =R B1 =R B0 ,

[0103] So the above equation can be simplified to:

[0104]

[0105] Combining the terms we get:

[0106]

[0107] Removing the negative sign from the right side of the equation yields:

[0108]

[0109] This is the same as:

[0110]

[0111] Therefore, in this model, the change in airway wall tissue temperature over time (ΔT A ) and the impedance drop over time (R T1 -R T0 ) divided by the product of the airway wall resistance (R A1 ·R A0 ) are proportional.

[0112] Impedance drop %, ratio of impedance change to the product of start and valley impedance

[0113] Reference now Fig. 9 , the impedance between the active electrode and the discrete electrodes can be measured over time. A typical impedance trace shows that the initial impedance (R T0 When tissue heating reaches the valley impedance (R T1), the impedance dropped rapidly within the first 20-30 seconds of treatment, during which no further significant drop in impedance was observed. As mentioned above, the impedance drop is the initial impedance (R T0 ) and valley impedance (R T1 ). Therefore, the impedance drop percentage (%) can also be calculated as follows:

[0114]

[0115] The percentage impedance drop occurs only in the near-field tissue due to tissue heating, ion dissociation, and ion excitation. This can provide real-time feedback on ablation and can provide insight into the intrinsic impedance of the airway wall.

[0116] Additionally or alternatively, using this information, the ratio of the impedance change to the product of the onset and trough impedances can also provide real-time feedback on ablation and can provide insight into the intrinsic impedance of the airway wall. The ratio can be calculated as follows:

[0117]

[0118] Reference now Figures 10A-10C , benchtop ablation of meat products (i.e., pork chops) was used to simulate airway wall tissue to confirm whether the impedance drop %, Δ ratio, and current were proportional to the impedance ratio. Different impedance ratios (R ) of 0.3, 0.4, 0.55, and 0.7 were evaluated at a constant power setting of 32 W. AW / R Tot ). As shown, the impedance drop %, delta ratio, and current are each proportional to the impedance ratio, with high R-squared values ​​exceeding 95%.

[0119] Reference now Figures 11A-11C , using an animal model to study the correlation between the depth of action (i.e., ablation lesion) and the impedance drop %, Δ ratio, and current. As shown in the figure, as the impedance drop %, Δ ratio, and current increase, the depth of action increases, with an acceptable R square value of more than 50%.

[0120] Based on the above theory and models, various algorithms may be considered to compensate for the variability of patient tissue and therefore resistance in real time (ie, during treatment) to achieve improved treatment efficacy.

[0121] Treatment Algorithm

[0122] Using the above mathematical model, in the first embodiment, reference Fig.12, the treatment method 1200 includes starting treatment 1202 at time = 0 by delivering current to the electrodes via the generator of the console. The desired target current is set by the user or programmed into the console. In a non-limiting embodiment, the desired target current range can be about 0.1Amp (A) to about 1.0A, more specifically, for high target current, about 0.3A to about 0.7A, where the preferred default value is 0.5A; and for low target current, about 0.2A to about 0.5A, where the preferred default value is 0.4A, in increments of 0.05A. In this embodiment, the power of the electrode is changed to maintain the desired target current, and must be operated within the maximum power of the generator (e.g., 50W), otherwise the generator will automatically shut down.

[0123] In this embodiment, at 1204, the console is programmed to begin calculating the following impedance drop %:

[0124]

[0125] And the impedance drop % will continue to be calculated throughout the treatment time. The target impedance drop % is also programmed into the console. In a non-limiting embodiment, for low and high drop targets, the target impedance drop % can range from about 5% to about 40%, with a preferred target of 32%.

[0126] At 1206, at any time during the treatment, if the % impedance drop target is reached before the target current, the console is programmed to maintain the current measured at the % drop target for the remaining treatment time. If the % impedance drop target is not reached, the console is programmed to maintain the target current for the remaining treatment time. In a non-limiting embodiment, the treatment time can be about two minutes. At 1208, at the end of the treatment time, the console stops the generator from delivering current to the electrodes.

[0127] In another embodiment (not shown), a constant current is delivered to the electrodes throughout the treatment time, within the maximum power limit of the system generator. In this embodiment, the power is adjusted (within the maximum power limit) to maintain the desired constant target current. Similar to the previous embodiment, the desired target current can range from about 0.1Amp (A) to about 1.0A, and more specifically, for high target currents, the range is about 0.3A to about 0.7A, with a preferred default value of 0.5A; and for low target currents of 5A, the range is about 0.2A to about 0.5A, with a preferred default value of 0.4A, in increments of 0.05A. In this embodiment, the power of the generator is varied to maintain the desired target current, and must be operated within the maximum power of the generator (e.g., 50W), otherwise the generator will automatically shut down. In this embodiment, the impedance response is not used as a parameter.

[0128] In yet another embodiment (not shown), the console adjusts the current (within the maximum power setting of the generator) to maintain the desired impedance drop %, which is calculated continuously from time = 0 throughout the treatment period. Fig. 9 Similar to the embodiments of the present invention, the target impedance drop % may range from about 5% to about 40% for low and high drop targets, with a preferred target being 32%.

[0129] In yet another embodiment, reference Fig.13 , the treatment method 1300 includes starting treatment 1302 at time = 0 by delivering current to the electrodes through the generator of the console. The desired target current is set by the user or programmed into the console. In a non-limiting embodiment, the desired target current can range from about 0.1Amp (A) to about 1.0A, more specifically, for high target current, the range is about 0.3A to about 0.7A, where the preferred default value is 0.5A; and for low target current, the range is about 0.2A to about 0.5A, where the preferred default value is 0.4A, and the increment is 0.05A. In this embodiment, the power of the generator is dynamically changed to maintain the desired target current, and must be operated within the maximum power of the generator (e.g., 50W), otherwise the generator will automatically shut down.

[0130] At 1304, the desired target current is delivered during a first time interval of the total treatment time, such as the first 30 seconds of a two-minute treatment time. During the first time interval, the impedance value is monitored, and the impedance lower limit value (Z) during the time interval is monitored. 30 ). At 1306, at the end of the first time interval, the system switches from constant current to constant power within the selected maximum power limit. In a non-limiting embodiment, the power limit ranges from about 30W to about 50W, with a preferred default setting of 40W for high power and 34W for low treatment.

[0131] During the second treatment time interval, the power is kept constant until the total treatment time ends and the impedance is continuously measured and monitored. However, if the measured impedance is greater than the sum of the lowest impedance value of the first time interval and the predetermined impedance value (Z 30 +Z D2 ), the console will enter a warning mode, or will shut down completely. In a non-limiting embodiment, the predetermined impedance value (Z D2 ) is about 25 ohms. If this does not occur during treatment, then at 1308, the console stops delivering current to the electrodes at the end of the treatment time.

[0132] In another embodiment of the present invention, reference Fig.14, to further improve normalization or maximization of near-field tissue heating, method 1400 includes adjusting the power of the system to maintain a small positive impedance slope during ablation or treatment. This small positive slope of impedance is associated with a slow rise in impedance, which can result in more effective or durable treatment because burning or overheating of the tissue is avoided. The positive slope indicates a bias in the heating / cooling balance in the direction of more heating without overheating the tissue. Overheating / burning of the tissue will be manifested by a rapid rise in impedance or a large positive impedance slope. Using this approach, all ablations or treatments achieve similar maximum tissue temperatures regardless of the variability of near-field tissue impedance or the variability of electrode contact.

[0133] Specifically, at 1402, treatment is initiated by powering the electrodes. At 1404, for a first time interval, such as but not limited to 30 seconds, a target power or target current is delivered to the electrodes to preheat the tissue to be treated. At this time, impedance is continuously measured and monitored, and the impedance slope percentage is calculated by:

[0134]

[0135] Optionally, during the first time interval, an impedance limit threshold may be set (eg, 10 ohms above the starting impedance) to prevent any runaway impedance condition.

[0136] At 1406, after the first time interval ends, the power and / or current (within maximum limits) are dynamically changed to maintain the target impedance slope for the remaining treatment time or a second time interval (e.g., but not limited to, 90 seconds). In a non-limiting example, the target impedance slope ranges from about 1% to about 30% within a maximum power and / or current limit range of about 26W-38W and 0.3A-0.5A, respectively. Optionally, within the second time interval, an impedance limit threshold can be set, such as, for example, 10-50 ohms higher than the lowest impedance value of the first time interval, or a maximum percentage slope of, for example, 10%-90% (depending on the target impedance slope) to prevent any runaway impedance conditions. If the maximum impedance, current, and / or power limit is reached, the console will enter a warning mode or will shut down completely. If there is no such situation, then at 1408, at the end of the treatment time, the console stops delivering current to the electrodes. The treatment time can be a set time, such as a total of two minutes, or it can vary according to the impedance slope % to achieve the desired effect.

[0137] In another embodiment of the present invention, reference Fig.15 To further improve the consistency of the ablation produced in the airway, the method utilizes an additional electrode to the set of electrodes to determine or approximate the tissue resistance R of the airway during active treatment. A , to maintain constant power delivery P to the airway wall A , even if the body resistance changes. Figure 4 , in a monopolar RF system, based on the formation of the patient monopolar circuit resistance component R T Due to the variability of the electrical properties of the airway and the amount of tissue, the power delivered to the target tissue to achieve a therapeutic effect varies significantly between patients. T Two patients treated with the same total power will have different amounts of power deposited on the airway walls. It is known that using conventional monopolar systems only the total patient resistance R T , the amount of power delivered to the airway wall will vary proportionally based on the ratio of the airway resistance to the total resistance.

[0138] P A =(R A / (R T ))×P T

[0139] Using this approach, all ablations or treatments are performed with the same power deposited at the airway wall, regardless of near-field tissue impedance variability or body tissue impedance variability.

[0140] Specifically, during activation, at 1502R A This method is used for continuous active monitoring. Then, in response to R A The change of total power P T , in order to maintain the deposition on the airway wall P A In a non-limiting example, the target power P A can vary between 11W and 23W. Optionally, at 1504, R A An impedance threshold may be set, such as 10-50 ohms above the lowest impedance value during the first 30 seconds of energy delivery, or a maximum percentage slope value may be set, such as 10%-90% (depending on the target impedance slope), to prevent any runaway impedance conditions.

[0141] By combining one or more algorithms, treatment variability, such as variability in patient tissue and / or electrode contact, can be reduced, thereby enhancing the effectiveness and durability of the ablation therapy.

[0142] A number of embodiments of systems, devices and methods have been described herein. These embodiments are given by way of example only and are not intended to limit the scope of the claimed invention. In addition, it should be understood that the various features of the embodiments described may be combined in a variety of ways to produce many other embodiments. In addition, although various materials, sizes, shapes, configurations, and positions, etc. have been described for use in the disclosed embodiments, other materials, sizes, shapes, configurations, positions, etc. other than those disclosed may be used without exceeding the scope of the claimed invention.

[0143] Those of ordinary skill in the relevant art will recognize that the subject matter herein may include fewer features than those shown in any of the individual embodiments described above. The embodiments described herein are not meant to be an exhaustive introduction to the various possible combinations of features of the subject matter. Therefore, as will be appreciated by those of ordinary skill in the art, the embodiments are not mutually exclusive combinations of features; rather, the various embodiments may include combinations of different individual features selected from different individual embodiments. Furthermore, unless otherwise noted, elements described with respect to one embodiment may also be implemented in other embodiments even if not described in these embodiments.

[0144] Although a dependent claim may refer to a specific combination with one or more other claims in a claim, other embodiments may also include a combination of a dependent claim with the subject matter of each other dependent claim or a combination of one or more features with other dependent or independent claims. Unless it is stated that a specific combination is not intended to be used, such combination is proposed herein.

[0145] Any document incorporated by reference above is limited so that no subject matter is introduced that is expressly contrary to the disclosure herein. Any document incorporated by reference above is further limited so that any claims included in the document are not incorporated herein by reference. Any document incorporated by reference above is further limited so that any definitions provided in the document are not incorporated herein by reference unless expressly included herein.

[0146] For purposes of claim interpretation, it is expressly intended that the provisions of 35 USC §112(f) not be invoked unless the specific terms "means for" or "step for" are recited in a claim.

Claims

1. A system for ablating target tissue of a patient's airway during treatment, the system include: an ablation assembly configured to be placed within the airway, the ablation assembly comprising an active energy emitter configured to contact an airway wall of the airway, and wherein the active energy emitter is configured to deliver energy to target tissue of the airway to ablate the target tissue, the target tissue being spaced radially outward from the energy emitter; and A controller is configured to control energy delivery from an energy source to the energy emitter, wherein the controller is configured to modify one of power and current of the system to achieve a predetermined output value during at least a treatment period.

2. The system of claim 1, wherein the power is dynamically changed during the at least one treatment period to achieve a predetermined current output. The system of claim 2 , wherein the power varies within a maximum power level.

4. The system of claim 1 , wherein the predetermined output value is a target current, wherein impedance of tissue at an energy emitter-tissue interface is measured during the treatment time, and wherein the controller is configured to: If the predetermined target impedance is reached before the target current is reached, the current is held constant; or If the predetermined target impedance is not met within the treatment time, the power is varied to achieve the target current.

5. The system of claim 4, wherein the predetermined target impedance is a percentage of impedance drop calculated according to the following formula: Where R TO is the impedance at the beginning of the treatment time, and R T实际 is the impedance at time t during the treatment time.

6. The system of claim 1 , wherein the controller is configured to dynamically change the power of the energy source to achieve a target current during a first treatment period, and at the end of the treatment period, the controller is configured to dynamically change the current of the energy source to achieve the target power during a second treatment period.

7. A system according to claim 6, wherein a sample of the lowest impedance value during the first treatment period is measured, and wherein the system is configured to indicate a warning or stop delivering energy if the impedance measured during the second treatment period exceeds the sum of the lower impedance value of the first period and a predetermined impedance value.

8. The system of claim 1, wherein the controller is configured to maintain one of the power or current constant during a first treatment period, During the second treatment period, the controller is configured to calculate the impedance slope percentage according to the following formula: Where Z O is the impedance at the beginning of the treatment time, Z 实际 is the impedance at time t during the treatment time, and t 0 -t 实际 is the time that has passed since the start of treatment, and Wherein the controller is configured to vary the power or current to maintain the impedance slope % within a predetermined range.

9. The system of claim 8, wherein impedance is measured during a first treatment period, and wherein the system is configured to indicate a warning or cease delivering energy if a predetermined impedance threshold is met or exceeded during the first treatment period.

10. A system according to claim 9, wherein a sample of the lowest impedance value during a first treatment period is measured, and wherein the system is configured to indicate a warning or stop delivering energy if the impedance measured during a second treatment period exceeds the sum of the lower impedance value of the first period and a predetermined impedance value.

11. The system of claim 8, wherein the system is configured to indicate a warning or to cease delivering energy if a predetermined % impedance slope value is met or exceeded during the second treatment time.

12. A method for ablating target airway tissue of a patient, the method include: providing a catheter assembly including an ablation assembly coupled to a distal end of an elongated shaft, the ablation assembly being configured to be placed within the airway to deliver energy to the target tissue, the ablation assembly including an energy emitter; placing the ablation assembly in the airway so that the energy emitter contacts the airway wall surface tissue of the airway; causing the energy transmitter to deliver energy to the airway wall for a treatment time to ablate the target tissue; as well as During energy delivery, one of the power and current of the energy transmitter is varied to achieve a predetermined output value for at least a treatment period.

13. The method of claim 12, wherein the power of the energy transmitter is varied during at least a treatment period to achieve a predetermined current value. The method of claim 13 , wherein the power varies within a maximum power level.

15. The method of claim 12, wherein the predetermined output value is a target current, the method further comprising: include: measuring impedance of tissue in contact with the energy transmitter during a treatment time; If a predetermined target impedance is reached before the target current is reached, maintaining the current constant; as well as If the predetermined target impedance is not met within the treatment time, the power is varied to achieve the target current.

16. The method of claim 15, wherein the predetermined target impedance is a percentage of impedance drop calculated according to the following formula: Where R TO is the impedance at the beginning of the treatment time, and R T实际 is the impedance at time t during the treatment time.

17. The method of claim 12, wherein changing one of the power and current to the energy transmitter include: The power is varied to achieve the target current during the first treatment period; and At the end of the treatment time, the current is changed to achieve the target power during the second treatment time.

18. The method according to claim 17, further comprising: include: The lowest impedance value was measured during the first treatment period; Impedance was measured during the second treatment period; as well as If the impedance measured during the second treatment period exceeds the sum of the lower impedance value of the first period and the predetermined impedance value, a warning is indicated or energy delivery is stopped.

19. The method according to claim 12, further comprising: include: maintaining one of the power or current constant at a predetermined level during a first treatment period; During the second treatment period, the impedance is measured and the impedance slope percentage is calculated according to the following formula: Where Z O is the impedance at the beginning of the treatment time, Z 实际 is the impedance at time t during the treatment time, and t 0 -t 实际 is the time that has passed since the start of treatment; as well as The power or current is varied during the second treatment period to maintain the impedance slope % within a predetermined range.

20. The method of claim 19, wherein impedance is measured during a first treatment period, and the method further comprises: include: If a predetermined impedance threshold is met or exceeded during the first treatment period, a warning is indicated or energy delivery is stopped.

21. The method according to claim 20, further comprising: include: The lowest impedance value is measured during the first treatment period, and If the impedance measured during the second treatment period exceeds the sum of the lower impedance value of the first period and the predetermined impedance value, a warning is indicated or energy delivery is stopped.

22. The method according to claim 20, further comprising: include: If a predetermined % impedance slope value is met or exceeded during the second treatment period, a warning is indicated or energy delivery is stopped.

23. A system for ablating target tissue of a patient's airway during treatment, the system include: an ablation assembly configured to be placed within the airway, the ablation assembly comprising a first electrode configured to contact an airway wall of the airway; a second electrode configured to be positioned outside of the airway; wherein the first electrode is configured to deliver energy to target tissue of the airway to ablate the target tissue, the target tissue being spaced radially outward from the energy emitter, and wherein the system is configured to measure impedance between the first electrode and the second electrode to estimate airway wall resistance; as well as A controller is configured to control energy delivery from an energy source to the first electrode, wherein the controller is configured to modify a current of the system based on the airway wall resistance to maintain constant power for at least a treatment time.

Citation Information

Patent Citations

  • Delivery devices with coolable energy emitting assemblies

    US20110152855A1

  • Delivery devices with coolable energy emitting assemblies

    US20130289556A1

  • Fluid delivery system and method for treatment

    US20140276792A1

  • Systems, assemblies, and methods for treating a bronchial tree

    US8088127B2

  • Apparatus for treating asthma using neurotoxin

    US8172827B2